跳至主要内容
临床试验/NCT04294940
NCT04294940撤回不适用

Impact of a Digital Solution (CardiCare™) on Cardiorespiratory Fitness Improvement in Patients Discharged From a Phase 2 Cardiac Rehabilitation Following an Acute Coronary Syndrome

Ad scientiam10 个研究点 分布在 4 个国家开始时间: 2021年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
发起方
Ad scientiam
试验地点
10
主要终点
To evaluate the efficacy at 6 months of CardiCare™ in stabilising or improving the Cardiorespiratory Fitness of patients after acute coronary syndrome, graduated from a phase 2 cardiac rehabilitation program, versus standard care.

研究概览

简要总结

Coronary heart disease is a partial inability of the coronary arteries to supply the heart muscle due to their narrowing. There is angina and myocardial infarction. Coronary heart disease is the first cause of non-communicated deaths and years of life lost.

After hospital discharge, a few days following the acute care of a coronary heart disease, a formal Cardiac Rehabilitation programme (CR) is usually provided. CR is a comprehensive programme involving exercise training, risk factor modification, education and psychological support. It is generally sequenced in 4 phases. Phase 1 begins at the hospital and consists of early mobilisation and education. Most phase 2 CR models are based upon supervised ambulatory outpatient programmes. Maintenance (phase 3 and 4) follows the ambulatory programme in which physical fitness and risk factor control are supported in a minimally supervised setting.

Despite high-grade recommendations and abundant clinical evidence, a CR program is not always implemented and the patients are not systematically referred after discharge from a phase 1 CR. Furthermore, compliance to pharmacological treatments and changes in lifestyle and diet are hugely neglected following a phase 2 CR and an important number of patients resume a sedentary lifestyle.

A growing body of evidence supports the use of digital tools such as smartphones and tablets in helping the patients achieve their goals in terms of physical exercise, risk-factor reduction and diet improvement.

Ad Scientiam has developed CardiCare™, a mobile application intended to provide a personalised physical training plan contributing to stabilise or improve cardiorespiratory fitness through improvement of VO2max.

The mobile application CardiCare™ is to be used by patients after an acute coronary syndrome, graduated from a phase 2 cardiac rehabilitation program in a cardiac rehabilitation centre and entering in phase 3 CR.

The mobile application CardiCare™ consists of several modules:

  • A physical activity recommendation engine, providing personalised weekly activity schedule, self-adapting to the patient's clinical characteristics, physical capacity and sport preferences through a proprietary algorithm
  • Self-administered questionnaires to assess perceived exertion, chest pain, weight variations, patient's quality of life
  • Passive monitoring of the patient's physical activity through Apple's HealthKit and Google's Fit
  • Informational content about cardiovascular diseases, risk factor reduction and chest pain action plan The investigator's work hypothesis is that, compared to standard care, CardiCare™ will stabilise or improve the cardiorespiratory fitness (VO2max) acquired post-CR.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Subjects ≥ 18 years old.
  • •Diagnosis of an Acute Coronary Syndrome in the last 3 months, documented by angiographically-proven coronary artery disease or hospitalisation report.
  • •Graduated from a phase 2 cardiac rehabilitation, ready to enter a phase 3 CR at home.
  • •Having agreed to perform a cardiopulmonary exercise testing and blood count at the inclusion or having performed a cardiopulmonary exercise testing and blood count within the last week.
  • •Owning a personal smartphone (Android 5.0 or beyond / iPhone 5s and newer supporting IOS 12 and beyond) with Wifi or a data plan (3G/4G).
  • •Able to use a smartphone (e.g. no vision, hearing, cognitive or dexterity impairment).
  • •Having agreed to install CardiCare™ application on their own smartphone.
  • •Having agreed to wear an actigraph at all times and install the actigraph application (CenterPoint Sync) on their smartphone.
  • •Enrolled in or benefiting of a national health system.
  • •Having read the information sheet and signed the informed consent form.
  • •Non-inclusion Criteria:
  • •Treated with Coronary Artery Bypass Grafting.
  • •Cardiac surgery in the last 12 weeks.
  • •Planned revascularisation or surgery in the next 6 months.
  • •Clinical heart failure or Left Ventricular Ejection Fraction < 40% documented within the last 2 months.
  • •Severe valvular disease.
  • •Severe pulmonary disease.
  • •Chronic kidney disease (stages III-V).
  • •Drug or/and alcohol abuse (as per clinician's judgment).
  • •Unstable angina.
  • •Osteoarticular condition or other reasons that limit exercise for more than 4 months (clinician's judgment).
  • •Uncontrolled hypertension (resting Diastolic BP>100 mmHg and resting Systolic BP >200 mmHg).
  • •Severe/uncontrolled arrhythmia.
  • •Systemic medical diseases that are likely to affect cognitive functioning.
  • •Pregnant women confirmed by a pregnancy test at the inclusion.
  • •Participation to another interventional clinical trial (category 1).
  • •Illiterate or not proficient in the language of the study country (French, Italian, Spanish or Portuguese according to the country).
  • •Person under guardianship or curatorship.

排除标准

  • 未提供

研究组 & 干预措施

Group A: standard of care

Other

The patient will follow the hygiene-dietetic recommendations given by their centre and wear an actigraph night and day.

干预措施: Wear an actigraph (Other)

Group B: standard of care + mobile application CardiCare™

Other

The patient will follow the hygiene-dietetic recommendations given by their centre, wear an actigraph night and day and use the mobile application CardiCare™

干预措施: Use the mobile application CardiCare™ and wear an actigraph (Other)

结局指标

主要结局

To evaluate the efficacy at 6 months of CardiCare™ in stabilising or improving the Cardiorespiratory Fitness of patients after acute coronary syndrome, graduated from a phase 2 cardiac rehabilitation program, versus standard care.

时间窗: From day 0 to month 6

Proportion of participants with stabilised or improved VO2max 6 months, as measured by Cardiopulmonary Exercise Test in group B versus group A

次要结局

  • To evaluate, for each session, the correlation between self-reported physical activities in CardiCare™ and those collected by the actigraph in group B.(From day 0 to month 6)
  • To identify patterns of VO2max evolution between D0, M3 and M6, between both groups(From day 0 to month 3 and month 6)
  • To evaluate CardiCare™ impact on sleep quality between groups over time of follow-up.(From day 0 to month 6)
  • To evaluate CardiCare™ impact on exercise performed in group B.(From day 0 to month 6)
  • To evaluate CardiCare™ impact on change in weight at 3 months and 6 months versus baseline in both groups.(From day 0 to month 3 and month 6)
  • To evaluate CardiCare™ impact on global physical activity between both groups over time of follow-up.(From day 0 to month 6)
  • To evaluate CardiCare™ impact on change in cardiorespiratory fitness at 3 months versus baseline in both groups.(From day 0 to month 3)
  • To evaluate CardiCare™ impact on change in other cardiorespiratory fitness parameters at 3 and 6 months versus baseline, in both groups(From day 0 to month 3 and month 6)
  • To evaluate CardiCare™ impact on change in lipid levels at 3 and 6 months versus baseline, in both groups.(From day 0 to month 3 and month 6)
  • To evaluate CardiCare™ impact on change in glucose levels at 3 and 6 months versus baseline, in both groups.(From day 0 to month 3 and month 6)
  • To evaluate CardiCare™ impact on change in Body Mass Index at 3 months and 6 months versus baseline in both groups.(From day 0 to month 3 and month 6)
  • To compare differences of reported cardiovascular events at 3 and 6 months, in both groups.(From day 0 to month 3 and month 6)
  • To evaluate CardiCare™ impact on change in Hip and waist circumference at 3 months and 6 months versus baseline in both groups.(From day 0 to month 3 and month 6)
  • To evaluate the impact of CardiCare™ on anxiety at 3 and 6 months versus baseline, in both groups.(From day 0 to month 3 and month 6)
  • To evaluate the impact of CardiCare™ on quality of life at 3 and 6 months versus baseline, in both groups.(From day 0 to month 3 and month 6)
  • To evaluate medication compliance in both groups.(From day 0 to month 6)
  • To assess the cost-effectiveness to reduce 30-day, 3 months and 6 months readmission rates using CardiCare™ as an intervention compared to standard care.(From day 0 to month 3 and month 6)
  • To evaluate CardiCare™ impact on cardiovascular risk factors control at 3 and 6 months versus baseline in both groups.(From day 0 to month 3 and month 6)
  • To compare time to first hospital readmission among both groups (all-cause, cardiac, and noncardiac) and their predictors.(From day 0 to month 3 and month 6)
  • To evaluate the impact of CardiCare™ on employment status at 3 and 6 months versus baseline in both groups.(From day 0 to month 3 and month 6)
  • To collect patients and investigators feedback on the CardiCare™ application.(From day 0 to month 6)
  • To evaluate the safety of the CardiCare™ use.(From day 0 to month 6)

研究者

发起方
Ad scientiam
申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验